LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
According to the press release, LIXTE is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LB-100, its lead compound and first-in-class clinical PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm.
LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
The company raised more than $11 million to strengthen its balance sheet, underscoring its commitment to advancing its pipeline. The full press release is available at https://ibn.fm/LP6QH.
Forward-looking statements in the release are subject to risks and uncertainties, as detailed in the Company's filings with the SEC, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on these statements, and the Company undertakes no duty to update them unless required by law.
